Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.35 |
| ▸ | CNR1 | P21554 | 6/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.35 |
| ▸ | ABHD12 | Q8N2K0 | 1/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 3/20 | 0.31 |
| ▸ | CCR3 | P51677 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGAV | P06756 | 1/20 | 0.31 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.31 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25548766 | 0.89 | CXCR2 (0.44) | CXCR2SLC6A5PDE2AITGB1 | |
| SCHEMBL23460875 | 0.89 | CXCR2 (0.46) | CNR2CNR1CXCR2SLC6A5 | |
| SCHEMBL38146973 | 0.89 | CXCR2 (0.46) | CNR2CNR1CXCR2SLC6A5 | |
| SCHEMBL23460874 | 0.89 | CXCR2 (0.46) | CNR2CNR1CXCR2SLC6A5 | |
| SCHEMBL23461460 | 0.87 | CXCR2 (0.37) | CNR2CNR1CXCR2FFAR4ABHD6 | |
| SCHEMBL38146994 | 0.87 | CXCR2 (0.37) | CNR2CNR1CXCR2FFAR4ABHD6 | |
| SCHEMBL23461461 | 0.87 | CXCR2 (0.37) | CNR2CNR1CXCR2FFAR4ABHD6 | |
| SCHEMBL38146971 | 0.86 | CXCR2 (0.45) | CNR2CNR1CXCR2ABHD12FFAR4 | |
| SCHEMBL23461032 | 0.86 | CXCR2 (0.45) | CNR2CNR1CXCR2ABHD12FFAR4 | |
| SCHEMBL25548770 | 0.85 | CXCR2 (0.45) | CXCR2SLC6A5PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | CNR2 716/4885CNR1 1450/4885CXCR2 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.